Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
暂无分享,去创建一个
D. Gladman | D. M. van der Heijde | P. Mease | M. Okada | M. Kishimoto | O. Benichou | C. Shuler | S. Rathmann | H. Carlier | S. Moriarty